Safety and side effects of cannabidiol, a Cannabis sativa constituent

Current Drug Safety

Volumn 6, Issue 4, 2011, Pages 237-249

  Bergamaschi, Mateus Machado ^a   Queiroz, Regina Helena Costa ^a   Zuardi, Antonio Waldo ^a   Crippa, José Alexandre S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cannabidiol; Cannabinoid; Cannabis sativa; CBD; Marijuana; Safety; Side effects; Toxicity

Indexed keywords

CANNABIDIOL; CANNABIS; ESTROGEN RECEPTOR; GLYCOPROTEIN P; NEUROLEPTIC AGENT; SEX HORMONE;

BLOOD PRESSURE; BODY TEMPERATURE; CATALEPSY; CELL VIABILITY; DRUG METABOLISM; FERTILIZATION; FOOD INTAKE; HAPLORHINI; HEART RATE; HUMAN; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INTESTINE TRANSIT TIME; MEMORY; MENTAL FUNCTION; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; REPRODUCTION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SKIN CONDUCTANCE;

EID: 83455262550     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488611798280924     Document Type: Review

References (132)

1. Grlie L. A comparative study on some chemical and biological characteristics of various samples of cannabis resin. Bull Narcot 1976; 14: 37-46.
2. Mehmedic Z, Chandra S, Slade D, et al. Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 2010; 55: 1209-17.
3. Potter DJ, Clark P, Brown MB. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 2008; 53: 90-4.
4. Perez-Reyes M, Timmons MC, Davis KH, Wall ME. A comparison of the pharmacological activity in man of intravenously administered delta-9-tetrahydrocannabinol, cannabinol and cannabidiol. Experientia 1973; 29: 1368-9.
5. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982; 76: 245-50.
6. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008; 153(2): 199-215.
7. Zuardi AW, Hallak JE, Crippa JA. Interaction between cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology (Berl) 2011; [Epub ahead of print].
8. Adams R, Hunt M, Clark JH. Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. J Am Chem Soc 1940; 62: 196-200.
9. Mechoulam R, Shvo Y. The structure of cannabidiol. Tetrahedron 1963; 19: 2073-8.
10. Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980; 21: 175-85.
11. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006; 39(4): 421-9.
12. Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2008; 30(3): 271-80.
13. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Nonpsychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009; 30(10): 515-27.
14. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A 2006; 103(20): 7895-900.
15. Castillo A, Tolón MR, Fernández-Ruiz J, et al. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxicischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol Dis 2010; 37(2): 434-40.
16. Ligresti A, Moriello AS, Starowicz K, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 2006; 318(3): 1375-87.
17. Massi P, Vaccani A, Bianchessi S, Costa B, Macchi P, Parolaro D. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci 2006; 63(17): 2057-66.
18. Massi P, Valenti M, Vaccani A, et al. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a nonpsychoactive cannabinoid. J Neurochem 2008; 104: 1091-1100.
19. Paria BC, Das SK, Dey SK. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling. Proc Natl Acad Sci USA 1995; 92(21): 9460-4.
20. Hart CL, Ward AS, Haney M, Comer SD, Foltin RW, Fischman MW. Comparison of smoked marijuana and oral D9-tetrahydrocannabinol in humans. Psychopharmacology 2002; 164: 407-415.
21. Williams CM, Rogers PJ, Kirkham TC. Hyperphagia in pre-fed rats following oral D9-THC. Physiol Behav 1998; 65: 343-6.
22. Koch JE. Delta(9)-THC stimulates food intake in Lewis rats: effects on chow, high-fat and sweet high-fat diets. Pharmacol Biochem Behav 2001; 68: 539-43.
23. Riedel G, Fadda P, McKillop-Smith S, Pertwee RG, Platt B, Robinson L. Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol 2009; 156(7): 1154-66.
24. El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 2006; 168(1): 235-44.
25. Wiley JL, Burston JJ, Leggett DC, et al. CB1 cannabinoid receptormediated modulation of food intake in mice. Br J Pharmacol 2005; 145(3): 293-300.
26. Scopinho AA, Guimarães FS, Corrêa FM, Resstel LB. Cannabidiol inhibits the hyperphagia induced by cannabinoid-1 or serotonin-1A receptor agonists. Pharmacol Biochem Behav 2011; 98(2): 268-72.
27. Ignatowska-Jankowska B, Jankowski MM, Swiergiel AH. Cannabidiol decreases body weight gain in rats: involvement of CB2 receptors. Neurosci Lett 2011; 490(1): 82-4.
28. Moreira FA, Guimarães FS. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol 2005; 512(2-3): 199-205.
29. Varvel SA, Wiley JL, Yang R, et al. Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology (Berl) 2006; 186(2): 226-34.
30. Zuardi AW, Rodrigues JA, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl) 1991; 104(2): 260-4.
31. Fairbairn JW, Pickens JT. The oral activity of delta9-tetrahydrocannabinol and its dependence on prostaglandin E2. Br J Pharmacol 1979; 67(3): 379-85.
32. Pertwee RG. The ring test-a quantitative method for assessing the 'cataleptic' effect of cannabis in mice. Br J Pharmacol 1972; 46: 753-763.
33. Savitz J, Lucki I, Drevets WC. 5-HT1A receptor function in major depressive disorder. Prog Neurobiol 2009; 88: 17-31.
34. Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 2005; 30: 1037-1043.
35. Zanelati TV, Biojone C, Moreira FA, Guimarães FS, Joca SR. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol 2010; 159(1): 122-8.
36. Guimarães FS, Chiaretti TM, Graeff FG, Zuardi AW Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 1990; 100: 558-9.
37. de Filippis D, Iuvone T, D'Amico A, et al. Effect of cannabidiol on sepsis-induced motility disturbances in mice: involvement of CB receptors and fatty acid amide hydrolase. Neurogastroenterol Motil 2008; 20(8): 919-27.
38. Hayakawa K, Mishima K, Nozako M, Hazekawa M, Irie K, Fujioka M. Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism. J Neurochem 2007; 102(5): 1488-96.
39. Hiltunen AJ, Järbe TU, Wängdahl K. Cannabinol and cannabidiol in combination: temperature, open-field activity, and vocalization. Pharmacol Biochem Behav 1988; 30(3): 675-8.
40. Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J. Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci 2000; 899: 274-82.
41. Resstel LB, Joca SR, Moreira FA, Corrêa FM, Guimarães FS. Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats. Behav Brain Res 2006; 172(2): 294-8.
42. Chesher GB, Dahl CJ, Everingham M, Jackson DM, Marchant-Williams H, Starmer GA. The effect of cannabinoids on intestinal motility and their antinociceptive effect in mice. Br J Pharmacol 1973; 49(4): 588-94.
43. Hayakawa K, Mishima K, Nozako M, et al. Repeated treatment with cannabidiol but not D9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance. Neuropharmacology 2007; 52: 1079-87.
44. Dirikoc S, Priola SA, Marella M, Zsürger N, Chabry J. Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity. J Neurosci 2007; 27(36): 9537-44.
45. Darmani NA. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids. J Pharmacol Exp Ther 2002; 300(1): 34-42.
46. McQueen DS, Bond SM, Smith PJ, Balali-Mood K, Smart D. Cannabidiol lacks the vanilloid VR1-mediated vasorespiratory effects of capsaicin and anandamide in anaesthetised rats. Eur J Pharmacol 2004; 491(2-3): 181-9.
47. De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011; 163(7): 1479-94.
48. Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001; 134(4): 845-52.
49. Shook JE, Burks TF. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 1989; 249(2): 444-9.
50. Graham JD, Li DM. Cardiovascular and respiratory effects of cannabis in cat and rat. Br J Pharmacol 1973; 49(1): 1-10.
51. Alvarez FJ, Lafuente H, Rey-Santano MC, et al. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxicischemic newborn piglets. Pediatr Res 2008; 64(6): 653-8.
52. Campos AC, Guimarães FS. Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(8): 1517-21.
53. Resstel LB, Tavares RF, Lisboa SF, Joca SR, Corrêa FM, Guimarães FS. 5-HT1A receptors are involved in the cannabidiolinduced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 2009; 156(1): 181-8.
54. Campos AC, Guimarães FS. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl) 2008; 199(2): 223-30.
55. Moreira FA, Campos AC, Guimarães FS. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl) 2008; 199(2): 223-30.
56. Moreira FA, Aguiar DC, Guimarães FS. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(8): 1466-71.
57. Zuardi AW, Karniol IG. Changes in the conditioned emotional response of rats induced by Δ9-THC, CBD and mixture of the two cannabinoids. Arq Biol Tecnol 1983; 26: 391-7.
58. Schurr A, Livne A. Differential inhibition of mitochondrial monoamine oxidase from brain by hashish components. Biochem Pharmacol 1976; 25(10): 1201-3.
59. Heyser CJ, Hampson RE, Deadwyler SA. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J Pharmacol Exp Ther 1993; 264(1): 294-307.
60. Ruh MF, Taylor JA, Howlett AC, Welshons WV. Failure of cannabinoid compounds to stimulate estrogen receptors. Biochem Pharmacol 1997; 53(1): 35-41.
61. Hollister LE. Cannabidiol and cannabinol in man. Experientia 1973; 29: 825-6.
62. Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA. Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur J Pharmacol 1974; 28(1): 172-7.
63. Carlini EA, Masur J, Magalhães CCPB. Possível efeito hipnótico do cannabidiol no ser humano. Estudo preliminar. Ciência e Cultura 1979; 31: 315-322.
64. Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin Pharmacol Ther 1976; 19: 300-9.
65. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011; 36(6): 1219-26.
66. Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011; 25(1): 121-30.
67. Crippa JA, Zuardi AW, Hallak JE. Therapeutical use of the cannabinoids in psychiatry. Rev Bras Psiquiatr. 2010; 32(Suppl 1): S56-66.
68. Fusar-Poli P, Crippa JA, Bhattacharyya S, et al. Distinct effects of (delta)9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 2009; 66(1): 95-105.
69. Fusar-Poli P, Allen P, Bhattacharyya S, et al. Modulation of effective connectivity during emotional processing by Delta9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 2009; 24: 1-12.
70. Bhattacharyya S, Fusar-Poli P, Borgwardt S, et al. Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 2009; 66(4): 442-51.
71. Borgwardt SJ, Allen P, Bhattacharyya S, et al. Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry 2008; 64(11): 966-73.
72. Crippa JA, Zuardi AW, Garrido GE, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 2004; 29(2): 417-26.
73. Zuardi AW, Cosme RA, Graeff FG, Guimarães FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacology 1993; 7: 82-8.
74. Consroe PF, Carlini EA, Zwicker AP, Lacerda LA. Interaction of cannabidiol and alcohol in humans. Psychopharmacology 1979; 66: 45-50.
75. Hallak JE, Dursun SM, Bosi DC, et al. The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(1): 198-202.
76. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010; 35(3): 764-74.
77. Hallak JE, Machado-de-Sousa JP, Crippa JA, et al. Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Rev Bras Psiquiatr 2010; 32(1): 56-61.
78. Mincis M, Pfeferman A, Guimarães RX, et al. Chronic administration of cannabidiol in man. Pilot study. AMB Rev Assoc Med Bras 1973; 19(5): 185-90.
79. Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 1991; 40(3): 701-8.
80. Zuardi AW, Morais SL, Guimarães FS, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995; 56(10): 485-6.
81. Zuardi AW, Hallak JE, Dursun SM, et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 2006; 20(5): 683-6.
82. Zuardi AW, Crippa J, Dursun S, et al. Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol 2010; 24(1): 135-7.
83. Leweke FM, Koethe D, Gerth CW, et al. Cannabidiol as an antipsychotic. A double-blind, controlled clinical trial on cannabidiol vs amisulpride in acute schizophrenia. Eur Psychiatry 2007; 22: S14.02.
84. Zuardi AW, Crippa J, Hallak J, et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol 2009; 23(8): 979-983.
85. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10(4): 434-41.
86. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 2004; 59(5): 440-52.
87. Poli G, Fauci AS. Cytokine modulation of HIV expression. Semin Immunol 1993; 5(3): 165-73.
88. Moriuchi H, Moriuchi M, Combadiere C, Murphy PM, Fauci AS. CD8q T-cell derived soluble factor_s., but non B-chemokines RANTES, MIP-1a and MIP-1b suppress HIV-1 replication in monocytesrmacrophages. Proc Natl Acad Sci 1996; 93: 15341-5.
89. Cramer B, Verhoef J, Peterso, PK. Macrophages, cytokines, and HIV. J Lab Clin Med 1997; 129: 10-6.
90. Srivastava MD, Srivastava BI, Brouhard B. D9-Tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 1998; 40(3): 179-85.
91. Jenny M, Santer E, Pirich E, Schennach H, Fuchs D. Δ9-Tetrahydrocannabinol and cannabidiol modulate mitogen-induced tryptophan degradation and neopterin formation in peripheral blood mononuclear cells in vitro. J Neuroimmunol 2009; 207(1-2): 75-82.
92. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab 2002; 3: 175-87.
93. Wirleitner B, Neurauter G, Schroecksnadel K, Frick B, Fuchs D. Interferon-γ-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 2003; 10: 1581-91.
94. Schroecksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 2006; 364: 82-90.
95. Huang A, Fuchs D, Widner B, Glover C, Henderson DC, Allen-Mersh, TG. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 2002; 86, 1691-6.
96. Widner B, Laich A, Sperner-Unterweger B, Ledochowski M, Fuchs D. Neopterin production tryptophan degradation and mental depression: what is the link? Brain Behav Immun 2002; 16: 590-5.
97. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D. Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry 2003; 54: 906-14.
98. Russo S, Kema IP, Fokkema MR, et al. Tryptophan as a link between psychopathology and somatic states. Psychosom Med 2003; 65: 665-71.
99. Guzmán M. Effects on cell viability. Handb Exp Pharmacol 2005; (168): 627-42.
100. McKallip RJ, Jia W, Schlomer J, Warren JW, Nagarkatti PS, Nagarkatti M. Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol Pharmacol 2006; 70: 897-908.
101. Gallily R, Even-Chena T, Katzavian G, Lehmann D, Dagan A, Mechoulam R. Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk Lymphoma 2003; 44: 1767-73.
102. Lee CY, Wey SP, Liao MH, Hsu WL, Wu HY, Jan TR. A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. Int Immunopharmacol 2008; 8(5): 732-40.
103. Wu HY, Chu RM, Wang CC, Lee CY, Lin SH, Jan TR. Cannabidiol-induced apoptosis in primary lymphocytes is associated with oxidative stress-dependent activation of caspase-8. Toxicol Appl Pharmacol 2008; 226(3): 260-70.
104. Jones G, Pertwee RG. A metabolic interaction in vivo between cannabidiol and 1-tetrahydrocannabinol. Br J Pharmacol 1972; 45(2): 375-7.
105. Paton WDM, Pertwee RG. Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism. Br J Pharmacol 1972; 44: 250-61.
106. Bornheim LM, Everhart ET, Li J, Correia MA. Induction and genetic regulation of mouse hepatic cytochrome P450 by cannabidiol. Biochem Pharmacol 1994; 48(1): 161-71.
107. Narimatsu S, Watanabe K, Yamamoto I, Yoshimura H. Inhibition of hepatic microsomal cytochrome P450 by cannabidiol in adult male rats. Chem Pharm Bull 1990; 38(5): 1365-8.
108. Bornheim LM, Correia MA. Selective inactivation of mouse liver cytochrome P-4501IIA by cannabidiol. Mol Pharmacol 1990; 38: 319-26.
109. Bornheim LM, Correia MA. Purification and characterization of the major hepatic cannabinoid hydroxyiase in the mouse: A possible member of the cytochrome P-450IIC subfamily. Mol Pharmacol 1991; 40: 228-34.
110. Bornheim LM, Lasker JM, Raucy JL. Human hepatic microsomal metabolism of Δ1-tetrahydrocannabinol. Drug Metab Dispos 1992; 2: 241-6.
111. Jaeger W, Benet LZ, Bornheim LM. Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica 1996; 26(3): 275-84.
112. Guengerich FP. In: Ortiz de Montellano PR, Ed. Cytochrome P450: Structure, Mechanism, and Biochemistry. New York: Plenum Press. 1995; pp 473-535.
113. Bornheim LM. In: Watson RR, Ed. Biochemistry and Physiology of Substance Abuse. Boca Raton: CRC Press. 1989; pp 21-35.
114. Bornheim LM, Kim YK, Chen B, Correia MA. The Effect of Cannabidiol on Mouse Hepatic Microsomal Cytochrome P450-Dependent Anandamide Metabolism. Biochem Biophys Res Commun 1993; 197(2): 740-6.
115. Bornheim LM, Correia MA. Purification and characterization of a mouse liver cytochrome P450 induced by cannabidiol. Mol Pharmacol 1989; 36: 377-83.
116. Comelli F, Giagnoni G, Bettoni I, Colleoni M, Costa B. Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved. Phytother Res 2008; 22(8): 1017-24.
117. Bornheim LM, Everhart ET, Li J, Correia MA. Induction and genetic regulation of mouse hepatic cytochrome P450 by cannabidiol. Biochem Pharmacol 1994; 48(1): 161-71.
118. Stott CG, Ayerakwa L, Wright S, et al. Lack of human cytochrome P450 induction by Sativex. 17th Annual Symposium on the Cannabinoids. Saint-Sauveur, Quebec, Canada: International Cannabinoid Research Society 2007; p 211.
119. Stott CG, Guy GW, Wright S, et al. 2005b. The effects of cannabis extracts Tetranabinex and Nabidiolex on human cytochrome P450-mediated metabolism. June 27 2005; Clearwater, FL. International Cannabinoid Research Association. p 163.
120. Zhu HJ, Wang JS, Markowitz JS, et al. Characterization of Pglycoprotein inhibition by major cannabinoids from marijuana. J Pharmacol Exp Ther 2006; 317(2): 850-7.
121. Holland ML, Panetta JA, Hoskins JM et al. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem Pharmacol 2006; 71: 1146-54.
122. Holland ML, Allen JD, Arnold JC. Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol 2008; 591(1-3): 128-31.
123. Holland ML, Lau DT, Allen JD, Arnold JC. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br J Pharmacol 2007; 152(5): 815-24.
124. Schuel H, Schuel R, Zimmerman AM, Zimmerman S. Cannabinoids reduce fertility of sea urchin sperm. Biochem Cell Biol 1987; 65(2): 130-6.
125. Schuel H, Berkery D, Schuel R, Chang MC, Zimmerman AM, Zimmerman S. Reduction of the fertilizing capacity of sea urchin sperm by cannabinoids derived from marihuana. I. Inhibition of the acrosome reaction induced by egg jelly. Mol Reprod Dev 1991; 29(1): 51-9.
126. Reich R, Laufer N, Lewysohn O, Cordova T, Ayalon D, Tsafriri A. In vitro effects of cannabinoids on follicular function in the rat. Biol Reprod 1982; 27(1): 223-31.
127. Steger RW, Murphy LL, Bartke A, Smith MS. Effects of psychoactive and nonpsychoactive cannabinoids on the hypothalamic-pituitary axis of the adult male rat. Pharmacol Biochem Behav 1990; 37(2): 299-302.
128. Watanabe K, Motoya E, Matsuzawa N, et al. Marijuana extracts possess the effects like the endocrine disrupting chemicals. Toxicology 2005; 31; 206(3): 471-8.
129. Rosenkrantz H, Fleischman RW, Grant RJ. Toxicity of short-term administration of cannabinoids to rhesus monkeys. Toxicol Appl Pharmacol 1981; 58(1): 118-31.
130. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 2011; 163(7): 1344-64.
131. Agurell S, Halldin M, Lindgren JE, et al. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 1986; 38(1): 21-43.
132. Harvey DJ, Samara E, Mechoulam R. Comparative metabolism of cannabidiol in dog, rat and man. Pharmacol Biochem Behav 1991; 40(3): 523-32.